FDA (CBER)
GUIDANCE FINAL
Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry
Published: 10/14/2026Detected: 10/14/2026
Summary preview
Clarifies FDA CBER expectations for ensuring the suitability of blood and blood component donors, including quarantine/hold requirements for source plasma, to reduce risks of transmitting infectious diseases and other…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from FDA CBER.
More from FDA (CBER)
- Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy: Guidance for Industry10/14/2026
- Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method9/16/2026
- Potency Assessment of Active Immunotherapy Products8/19/2026
- Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products: Guidance for Industry8/19/2026
- Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus: Guidance for Industry6/29/2026